RITALIN Drug Patent Profile
✉ Email this page to a colleague
When do Ritalin patents expire, and what generic alternatives are available?
Ritalin is a drug marketed by Sandoz and Novartis and is included in three NDAs.
The generic ingredient in RITALIN is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ritalin
A generic version of RITALIN was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RITALIN?
- What are the global sales for RITALIN?
- What is Average Wholesale Price for RITALIN?
Summary for RITALIN
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 93 |
Clinical Trials: | 126 |
Patent Applications: | 4,488 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for RITALIN |
Drug Sales Revenues: | Drug sales revenues for RITALIN |
What excipients (inactive ingredients) are in RITALIN? | RITALIN excipients list |
DailyMed Link: | RITALIN at DailyMed |
![RITALIN drug patent expirations Drug patent expirations by year for RITALIN](/p/graph/s/t/RITALIN-patent-expirations.png)
![Drug Prices for RITALIN](/p/graph/drug-price/RITALIN.png)
![Drug Sales Revenue Trends for RITALIN](/p/graph/drug-sales-revenues/RITALIN.png)
Recent Clinical Trials for RITALIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Johns Hopkins University | Phase 4 |
University of Florida | Early Phase 1 |
University of Zurich | Phase 1 |
Pharmacology for RITALIN
Drug Class | Central Nervous System Stimulant |
Physiological Effect | Central Nervous System Stimulation |
US Patents and Regulatory Information for RITALIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sandoz | RITALIN | methylphenidate hydrochloride | TABLET;ORAL | 010187-003 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sandoz | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-003 | Jun 5, 2002 | AB1 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sandoz | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-004 | Apr 10, 2004 | AB1 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sandoz | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-005 | Oct 27, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |